KR102668593B1 - 생체내 영상화를 위한 프로테아제 활성화 조영제 - Google Patents

생체내 영상화를 위한 프로테아제 활성화 조영제 Download PDF

Info

Publication number
KR102668593B1
KR102668593B1 KR1020177023302A KR20177023302A KR102668593B1 KR 102668593 B1 KR102668593 B1 KR 102668593B1 KR 1020177023302 A KR1020177023302 A KR 1020177023302A KR 20177023302 A KR20177023302 A KR 20177023302A KR 102668593 B1 KR102668593 B1 KR 102668593B1
Authority
KR
South Korea
Prior art keywords
delete delete
group
compounds
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177023302A
Other languages
English (en)
Korean (ko)
Other versions
KR20180010177A (ko
Inventor
매튜 에스 보그요
마르테인 베르도스
레슬리 오포리
니말리 피 위타나
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20180010177A publication Critical patent/KR20180010177A/ko
Application granted granted Critical
Publication of KR102668593B1 publication Critical patent/KR102668593B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020177023302A 2015-01-22 2016-01-22 생체내 영상화를 위한 프로테아제 활성화 조영제 Active KR102668593B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106400P 2015-01-22 2015-01-22
US62/106,400 2015-01-22
PCT/US2016/014606 WO2016118910A1 (en) 2015-01-22 2016-01-22 Protease-activated contrast agents for in vivo imaging

Publications (2)

Publication Number Publication Date
KR20180010177A KR20180010177A (ko) 2018-01-30
KR102668593B1 true KR102668593B1 (ko) 2024-05-22

Family

ID=56417841

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177023302A Active KR102668593B1 (ko) 2015-01-22 2016-01-22 생체내 영상화를 위한 프로테아제 활성화 조영제

Country Status (6)

Country Link
US (3) US10570173B2 (cg-RX-API-DMAC7.html)
EP (1) EP3247802B1 (cg-RX-API-DMAC7.html)
JP (2) JP7017410B2 (cg-RX-API-DMAC7.html)
KR (1) KR102668593B1 (cg-RX-API-DMAC7.html)
CN (1) CN107406872B (cg-RX-API-DMAC7.html)
WO (1) WO2016118910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
US10405753B2 (en) * 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
GB201617935D0 (en) 2016-10-24 2016-12-07 Queens University Of Belfast The Binding compound and uses thereof
CN116217656B (zh) * 2016-12-23 2026-05-08 里兰斯坦福初级大学理事会 基于活性的探针化合物、组合物及其使用方法
CN110678460A (zh) * 2017-03-30 2020-01-10 里兰斯坦福初级大学理事会 用于体内成像的蛋白酶激活的造影剂
US20220105206A1 (en) * 2020-10-02 2022-04-07 Board Of Regents, The University Of Texas System Sensitivity advances in ultrasound switchable fluorescence systems and techniques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145257A2 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) * 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
WO1996041638A1 (en) 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US8133482B2 (en) * 2003-11-14 2012-03-13 The Trustees Of The University Of Pennsylvania Activatable photodynamic therapy agents
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
CN101583346B (zh) 2006-04-28 2015-08-19 儿童医院医疗中心 用于穿膜药物递送系统的皂化蛋白c和相关蛋白及肽的促融合性质
CN101652149B (zh) * 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
WO2008104271A2 (en) 2007-02-28 2008-09-04 Sanofi-Aventis Imaging probes
EP2148702A2 (en) * 2007-05-16 2010-02-03 GE Healthcare AS Pentamethine cyanine dyes carrying at least three sulfonic acid groups
MY148484A (en) 2007-08-03 2013-04-30 Sanofi Aventis Caspase imaging probes
US8343458B2 (en) 2008-04-03 2013-01-01 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
KR20110081147A (ko) * 2008-08-06 2011-07-13 더 텍사스 에이 앤드 엠 유니버시티 시스템 시험관 내 진단 및 생체 내 이미지화, 진단 및 치료를 위한 박테리아 베타-락타마제의 용도
AU2008363813A1 (en) 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
US9155471B2 (en) * 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
US9180209B2 (en) 2011-02-28 2015-11-10 The Board Of Trustees Of The Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
WO2012129128A1 (en) 2011-03-18 2012-09-27 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
US20140249468A1 (en) 2011-09-09 2014-09-04 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) * 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
WO2014152389A1 (en) 2013-03-14 2014-09-25 Lumicell, Inc. Imaging agent for detection of diseased cells
SG11201508185YA (en) * 2013-04-19 2015-11-27 Agency Science Tech & Res Tunable fluorescence using cleavable linkers
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
CN110678460A (zh) * 2017-03-30 2020-01-10 里兰斯坦福初级大学理事会 用于体内成像的蛋白酶激活的造影剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145257A2 (en) * 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use

Also Published As

Publication number Publication date
US10570173B2 (en) 2020-02-25
CN107406872B (zh) 2023-03-28
US20180002375A1 (en) 2018-01-04
JP7017410B2 (ja) 2022-02-08
EP3247802A4 (en) 2018-08-22
US20200299327A1 (en) 2020-09-24
WO2016118910A1 (en) 2016-07-28
EP3247802A1 (en) 2017-11-29
US12459972B2 (en) 2025-11-04
CN107406872A (zh) 2017-11-28
EP3247802B1 (en) 2024-08-28
US20240025945A1 (en) 2024-01-25
JP2022044770A (ja) 2022-03-17
JP2018511556A (ja) 2018-04-26
KR20180010177A (ko) 2018-01-30

Similar Documents

Publication Publication Date Title
US12459972B2 (en) Protease-activated contrast agents for in vivo imaging
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
US10829477B2 (en) Activity-based probe compounds, compositions, and methods of use
US20240077475A1 (en) Protease-activated contrast agents for in vivo imaging

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601